DOCSLIB.ORG

Product List 2018 WE LIVE SERVICE Certificates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product List 2018 WE LIVE SERVICE Certificates Product List 2018 WE LIVE SERVICE Certificates quartett owns a production site that is certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. Founded as a family-run company in 1986, quartett ensures for more than 30 years consistent quality of products. In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 supported this decision. The company specialized its product profile in manufacturing and modification of synthetic peptides with HPLC purity > 95 % including protease inhibitors or peptides for antibody production. Second expertise of quartett is the production of a variety of reagents for histology, cytology and immunohistochemistry including > 8000 antibodies and detection systems. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals and private doctor offices. But we are not only limited to provide our customers with consumable chemicals. Since quartett already offered cosmetic peptides, in 2011 we started working in the cosmetic field creating YOUmeDERM® care products. We have set ourselves the task to provide the best quality solutions in all spheres of research. quartett owns a production site that is certified according to EN ISO 9001:2008 & EN ISO 13485:2012 + AC:2012 and works in compliance with GMP conformity. Our quality management guarantees products of highest quality. Over the past decades we have steadily improved and enhanced our capabilities to satisfy your expectations. Service and support of our valued customers are our daily businesses. A network of worldwide distributors guarantees global customer supply. We participate at international exhibitions, such as MedLab in Dubai, Medica in Germany and various congresses for pathologists. Furthermore, we are represented by distributors at exhibitions we are not able to attend. After so many years it is again time to say thanks to each of our clients and business partners for trusting in us. Without them we were not as successful as we are and we are proud to have each of you in our quartett family. Welcome to quartett! Be part of us! 3 1. Antibodies 7 1.1. Antibodies for FFPE and Frozen Sections 7 1.2. Antibodies FITC-conjugated 172 2. Immunohistochemical Detection Systems 174 2.1. Streptavidin / Biotin Systems - ProTaqs® Essencial 175 2.2. Polymer Systems - ProTaqs® Suprema PolyColor 175 2.3. Polymer Systems - ProTaqs® Suprema DoubleStain 177 2.4. Polymer Systems - ProTaqs® Suprema TripleStain 179 2.5. Single Components for Immunhistochemical Detection Systems 180 2.5.1. Streptavidin and Enzyme Complexes 180 2.5.2. Secondary Antibodies 180 2.5.3. Secondary Antibodies for Double Staining Detection Systems 180 2.5.4. Chromogens for Alkaline Phosphatase 181 2.5.5. Chromogens for Horseradish Peroxidase 181 2.5.6. Sera 181 2.5.7. Chromogen Dilution Solutions 182 3. Reagents for Immunohistochemistry / Histology / Cytology 183 3.1. Histological / Cytological Stains 183 3.1.1. Stain Solutions 183 3.1.2. Fast Stains 184 3.1.3. Special Stains 185 3.2. Buffer 186 3.2.1. Buffer Bags with Pre-mixed Salts 187 3.2.2. Citrate Buffer / Citrate EDTA Buffer / EDTA Buffer 187 3.2.3. Michel’s Buffer 188 3.2.4. Phosphate Buffered Saline / PBS 188 3.2.5. TRIS Buffered Saline / TBS 190 3.2.6. TRIS EDTA Buffer / TRIS EDTA Citrate Buffer 191 3.2.7. Buffer for Electrophoresis 192 3.3. Antigen Retrieval 193 3.4. Antibody Diluents 194 3.5. Blocking Reagents 195 3.6. Mounting Media 195 3.7. Fixatives 196 3.8. Decalcifier 197 3.9. Intermedium - Xylene Alternative ProTaqs® Clear 198 4. Instruments for Histology 200 4.1. Humidity Chamber - Slide Humidore 200 4.2. Tissue Float Bath 3 in 1 *** IVD *** 201 5. Molecularbiology and In-situ-Hybridization jelly 202 by FProISHTaqs® 5.1. Fluorescence-In-situ-Hybridization (FISH) 202 5.1.1. ProTaqs® jellyFISH Probes 203 5.1.2. Pretreatment and FISH on Paraffin Tissues 206 5.2. Wash Solutions and Buffer 206 6. Accessories for Anatomy and Pathology 207 4 7. Peptides 209 7.1. Enzyme Inhibitors 209 7.1.1. Protease Inhibitors 209 7.1.2. Protease Inhibitor Cocktail Kits 216 7.1.3. Protease and Phosphatase Inhibitor Cocktail Kits 217 7.2. Collagenase Inhibitors 218 8. Services 219 8.1. Peptide Services 219 8.1.1. Custom Peptide Synthesis 219 8.1.2. Modification and Derivatization of Peptides 220 8.1.3. Isolation and Purifcation of Peptides 220 8.2. Sugar Amino Acids (SAAs) 221 8.3. Carbohydrates 221 8.4. Nucleosides 221 8.5. Custom Antibody Production Services 221 8.5.1. Polyclonal Antisera and Antibodies from Rabbit 221 8.5.2. Monoclonal Mouse Antibodies 222 8.5.3. Monoclonal Rabbit Antibodies 222 8.5.4. Modification of Mono- and Polyclonal Antibodies 222 9. Cosmetics 223 9.1. YOUmeDERM® Care Products 223 10. Conditions of Supply 226 10.1. Address 226 10.2. Orders 226 10.3. Shipments 226 10.4. Shipping Charges 226 10.5. Prices 226 10.6. Payment and Credit Terms 227 10.7. Returns and Cancellations 227 10.8. Limited Warranty 227 10.9. Breakages and Shortages 227 10.10. Reservation of Property Rights 227 10.11. Liabilities and Conditions 227 10.12. Applicable Law, Jurisdiction and Partial Invalidity 227 10.13. Technical Support 227 5 Explanations AP Alkaline Phosphatase Bov Bovine Ch Chicken Ct Cat Conc. Concentrate Cw Cow Dg Dog Du Duck EIA Enzymimmunoassay ELISA Enzyme-linked Immunosorbent Assay FACS Fluorescence-activated Cell Sorting FISH Fluorescence In-situ Hybridization Fs Fish Gp Guinea Pig Gt Goat HIER Heat Induced Epitope Retrieval Hm Hamster Hs Horse HRP Horseradish Peroxidase Hu Human IC or ICC Immunocytochemistry IF Immunofluorescence IH Immunohistology IHC(p,f) Immunohistochemistry (Paraffin, Frozen) IP Immunoprecipitation ISH In-Situ Hybridization LSAB Labeled Streptavidin / Biotin method mM Reacts w. most mammals Mk Monkey Ms Mouse Ov Ovine PIER Proteolytic Induced Epitope Retrieval Pg Pig Rb Rabbit RIA Radioimmunoassay Rt Rat RTU Ready-to-use Sam Salamander Sh Sheep WB Western Blot 6 1. Antibodies A 1.1. Antibodies for FFPE and Frozen Sections quartett offers more than 8000 antibodies for formalin fixed paraffin embedded and frozen sections. Almost all antibodies are available in the same formats. If you want to place an order, please follow our intructions for catalog number writing using the article master shown in the table. Example: Article Master: PR292; Product Name: PD-L1 (QR1) ▶ 100 µl concentrate: 1-PR292-02 ▶ 1 ml concentrate: 1-PR292-07 ▶ 3 ml ready-to-use: 2-PR292-10 ▶ 7 ml ready-to-use: 2-PR292-13 Just ask our customer service team for the correct order number, if you have difficulties or if you need another size than shown here. Cat. No. Product Name Source Clone Application Reactivity 00001 14-3-3 epsilon Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rb, Rt, ... 00002 14-3-3 pan (alpha, beta, gamma, delta, epsilon) Rb Polyclonal IHC(p*/f), WB Hu, Ms, Rt, ... 00003 14-3-3 pan (alpha, beta, gamma, delta, epsilon) Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... 00004 14-3-3 zeta Rb Polyclonal IHC(p*/f), WB Hu, Ms, Rt, ... 00005 2-aminoethanethiol dioxygenase/ADO Rb Polyclonal IHC(p*/f), WB Hu, Ms, Rt, ... 00006 2-oxoglutarate and iron dependent oxygenase domain contai- Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rb, Rt, ... ning 1/OGFOD1 00007 2-oxoglutarate and iron dependent oxygenase domain contai- Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... ning 2/OGFOD2 00008 2',3'-cyclic nucleotide 3' phosphodiesterase/CNP Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rb, Rt, ... 00009 2',5'-oligoadenylate synthetase 1/OAS1 Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, ... 00010 20S proteasome beta type subunit antibody proteasome com- Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... ponent C5/PRS3 00011 26S proteasome associated UCH interacting protein 1/UCH- Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... L5IP 00012 26S proteasome regulatory subunit S10/PSMD6 Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rb, Rt, ... 00013 3-hydroxyanthranilate oxygenase/HAAO Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... 00014 3-oxoacid CoA transferase 1/OXCT1 Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... 00015 3-phosphoglycerate dehydrogenase/PHGDH Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... 00016 4-N acetylglucosaminyltransferase/A4GNT Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... 00017 4'-phosphopantetheinyl transferase/AASDHPPT Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rb, Rt, ... 00019 5-methyl cytosine Rb Polyclonal IHC(p*/f), ELISA 00020 6-phosphofructo-1-kinase/fructose-1,6-bisphosphatase/PFK1 Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rb, Rt, ... 00021 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1/ Rb Polyclonal IHC(p*/f), ELISA, WB Hu, Ms, Rt, ... PFKFB1 Errors and misprints excepted. If you need help with the catalog number, just ask our customer service team.
Load more

Recommended publications
  • Genotyping for Response to Physical Training
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2019 Genotyping for Response to Physical Training Stacy Simmons Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Molecular Biology Commons Repository Citation Simmons, Stacy, "Genotyping for Response to Physical Training" (2019). Browse all Theses and Dissertations. 2109. https://corescholar.libraries.wright.edu/etd_all/2109 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. GENOTYPING FOR RESPONSE TO PHYSICAL TRAINING A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By STACY SIMMONS B.S., Wright State University, 2014 _________________________________________________________ 2019 Wright State University WRIGHT STATE UNIVERSITY GRADUATE SCHOOL July 29, 2019 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY Stacy Simmons ENTITLED Genotyping for Response to Physical Training BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. ___________________________________ Michael Markey, Ph.D. Thesis Director ____________________________________ Madhavi P. Kadakia, Ph.D. Committee on Chair, Department of Biochemistry Final Examination and
    [Show full text]
  • Gentaur Products List
    Chapter 2 : Gentaur Products List • Rabbit Anti LAMR1 Polyclonal Antibody Cy5 Conjugated Conjugated • Rabbit Anti Podoplanin gp36 Polyclonal Antibody Cy5 • Rabbit Anti LAMR1 CT Polyclonal Antibody Cy5 • Rabbit Anti phospho NFKB p65 Ser536 Polyclonal Conjugated Conjugated Antibody Cy5 Conjugated • Rabbit Anti CHRNA7 Polyclonal Antibody Cy5 Conjugated • Rat Anti IAA Monoclonal Antibody Cy5 Conjugated • Rabbit Anti EV71 VP1 CT Polyclonal Antibody Cy5 • Rabbit Anti Connexin 40 Polyclonal Antibody Cy5 • Rabbit Anti IAA Indole 3 Acetic Acid Polyclonal Antibody Conjugated Conjugated Cy5 Conjugated • Rabbit Anti LHR CGR Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Integrin beta 7 Polyclonal Antibody Cy5 • Rabbit Anti Natrexone Polyclonal Antibody Cy5 Conjugated • Rabbit Anti MMP 20 Polyclonal Antibody Cy5 Conjugated Conjugated • Rabbit Anti Melamine Polyclonal Antibody Cy5 Conjugated • Rabbit Anti BCHE NT Polyclonal Antibody Cy5 Conjugated • Rabbit Anti NAP1 NAP1L1 Polyclonal Antibody Cy5 • Rabbit Anti Acetyl p53 K382 Polyclonal Antibody Cy5 • Rabbit Anti BCHE CT Polyclonal Antibody Cy5 Conjugated Conjugated Conjugated • Rabbit Anti HPV16 E6 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti CCP Polyclonal Antibody Cy5 Conjugated • Rabbit Anti JAK2 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti HPV18 E6 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti HDC Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Microsporidia protien Polyclonal Antibody Cy5 • Rabbit Anti HPV16 E7 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Neurocan Polyclonal
    [Show full text]
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd
    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • TNF Decoy Receptors Encoded by Poxviruses
    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
    [Show full text]
  • Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate
    J. Ind. Eng. Chem., Vol. 12, No. 5, (2006) 757-761 Recombinant Escheichia coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate Sun-Gu Lee† and Byung-Gee Kim* Department of Chemical and Biochemical Engineering, Pusan National University, Busan 609-735, Korea *School of Chemical Engineering, and Institute of Molecular Biology and Genetics, Seoul National University, Seoul 151-742, Korea Received April 24, 2006; Accepted May 22, 2006 Abstract: A recombinant Escherichia coli overexpressing CMP-kinase was constructed and employed as a whole cell biocatalyst for the conversion of cytidine 5′-monophosphate to cytidine 5′-triphosphate. In the whole cell biocatalysis, recombinant CMP kinase catalyzed the conversion of CMP to CDP, and endogenous acetate kinase of the E. coli was utilized for the ATP regeneration as well as for the conversion of CDP to CTP. A conversion yield of ca. 88 % CTP was obtained when starting with 20 mM CMP, 1 mM ATP, and 80 mM acetyl phosphate based on the initial CMP concentration. Endogenous pyruvate kinase and poly- phosphate kinase were inefficient in the process. The CTP production system was applied to the production of CMP-NeuAc by additionally introducing the CMP-NeuAc synthetase gene into the recombinant E. coli. Keywords: CMP-kinase, whole cell biocatalysis, ATP regeneration, cytidine 5′-monophosphate Introduction employing enzymes [4]. They applied various enzymatic 1) methods and chemical methods and concluded that the As glycosyltransferase-catalyzed synthetic techniques enzymatic method based on adenylate kinase/pyruvate are becoming recognized as powerful methods for the kinase provided the most convenient route to CTP. In the preparation of biologically important oligosaccharides, process, CTP was generated efficiently from an inexpen- the development of cost-efficient production methods for sive substrate, CMP.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis
    Figure S1. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. A Figure S1. Continued. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. B Figure S2. Comparative analysis of the variant frequency found by the KCC71 panel and calculated from publicly available cBioPortal datasets. For each of the 71 genes in the KCC71 panel, the frequency of variants was calculated as the variant number found in the examined cases. Datasets marked with different colors and sample numbers of prostate cancer are presented in the upper right. *Significantly high in the present study. Figure S3. Seven subnetworks extracted from each of seven public prostate cancer gene networks in TCNG (Table SVI). Blue dots represent genes that include initial seed genes (parent nodes), and parent‑child and child‑grandchild genes in the network. Graphical representation of node‑to‑node associations and subnetwork structures that differed among and were unique to each of the seven subnetworks. TCNG, The Cancer Network Galaxy. Figure S4. REVIGO tree map showing the predicted biological processes of prostate cancer in the Japanese. Each rectangle represents a biological function in terms of a Gene Ontology (GO) term, with the size adjusted to represent the P‑value of the GO term in the underlying GO term database.
    [Show full text]
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • Datasheet BA3564-2 Anti-FES Antibody
    Product datasheet Anti-FES Antibody Catalog Number: BA3564-2 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-FES Antibody Gene Name FES Source Rabbit IgG Species Reactivity human,mouse,rat Tested Application WB Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen A synthetic peptide corresponding to a sequence at the C-terminus of human FES(808-822aa STIYQELQSIRKRHR). Purification Immunogen affinity purified. Observed MW Dilution Ratios Western blot: 1:500-2000 Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information FES(feline sarcoma oncogene) is an enzyme that in humans is encoded by the FES gene, also known as Proto-oncogene tyrosine-protein kinase Fes/Fps, Feline sarcoma/Fujinami avian sarcoma oncogene homolog, Proto-oncogene c-Fes, Proto-oncogene c-Fps, p93c-fes c-fes/fps protein, FPS, Oncogene FES, feline sarcoma virus, FPS. This gene encodes the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. Non-onc intervening sequences were present in the human counterpart. The gene product has tyrosine-specific protein kinase activity and that activity is required for maintenance of°Cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia, but it is also involved in normal hematopoiesis. A truncated transcript has been identified that is generated utilizing a start site in one of the far downstream exons but a protein product associated with this transcript has not been identified.
    [Show full text]
  • Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes
    Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis Hien-Anh Nguyen To cite this version: Hien-Anh Nguyen. Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis. Sciences agricoles. Université de Grenoble, 2012. Français. NNT : 2012GRENV017. tel-00721757 HAL Id: tel-00721757 https://tel.archives-ouvertes.fr/tel-00721757 Submitted on 30 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE Spécialité : Chimie-Biologie Arrêté ministériel : 7 août 2006 Présentée par Hien-Anh NGUYEN Thèse dirigée par le Dr. Jean-Michel JAULT préparée au sein de l’Institut de Biologie Structurale J.-P. Ebel, et du CEA de Grenoble dans l'École Doctorale Chimie et Sciences du Vivant Découverte d’une nouvelle famille de protéines kinases bactériennes : Mécanisme de fonctionnement et rôle cellulaire de YdiB, un représentant chez B. subtilis Thèse soutenue publiquement le 23 mai 2012 devant le jury composé de : Mme. Patricia DOUBLET Rapporteur Prof.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]